This would allow researchers to directly test the model’s predictions, such as the impact of sustained VEGF and ERK expression on aggressive tumor growth or the role of Glut-1 and OGT in metabolic shifts that support cancer proliferation. The gene discussed is SLC2A1; the disease is neoplasm.